FinTechsDepot FinTechsDepot - Empowering FinTech Futures: Where Knowledge Fuels Innovation.

  • HOME
  • ARTICLES
    • Digital banking
  • RESOURCES
    • Whitepaper
    • Infographics
  • GLOBENEWSWIRE NEWS
  • EVENTS
    • Upcoming conference
    • Past Conference
    • Webinar
  • Contact Us
FinTechsDepot
  • Home
  • Admin
  • Page 23

Author

Admin 425 posts 0 comments

Banking

Indian Banking Sector Shows Mixed Signals Amid Rising NPAs and Digital…

Admin Jul 30, 2025
The Indian banking sector is currently navigating a complex landscape marked by both promising growth and emerging…
Banking

7 Ways Property Claim Letters Cripple Your Cost-per-Claim

Admin Jul 29, 2025
Inefficient P&C claim letters hide significant costs. Discover how the application of AI for claims letters…
Featured News

Mixed Signals with Goldman Sachs

Admin Jul 28, 2025
In contrast to broader trends of job cuts in financial services, Goldman Sachs recently canceled a planned second…
Upcoming conference

Fintech Horizons 2025: Shaping the Future of Digital Finance

Admin Jul 25, 2025
The global fintech industry is gearing up for Fintech Horizons 2025, a premier conference bringing together…
Banking

How banks can innovate lightning fast

Admin Jul 24, 2025
As banking players have embraced the digital era, customers want to do more and more online and via their mobile…
Featured News

Understanding Income Tax in the Finance Industry

Admin Jul 23, 2025
Income tax remains one of the most crucial aspects of financial planning for individuals and businesses alike. In…
Articles

Three Community Banks Partner with iDENTIFY to Eliminate Data Silos

Admin Jul 22, 2025
In a move to modernize operations and streamline data management, three leading community banks have partnered…
Whitepaper

The E-Commerce Tax Compliance Imperative: Consistency = Credibility

Admin Jul 21, 2025
The substantial value e-commerce capabilities deliver to a business comes with a cost—heightened compliance…
Articles

How Fintech is Reshaping Global Payments

Admin Jul 18, 2025
The fintech industry is rapidly redefining the way people and businesses handle payments. With digital wallets,…
Banking

Strategic Investment Approaches in the Banking Sector: Navigating Growth and…

Admin Jul 17, 2025
The banking sector has long been a cornerstone of economic development, acting as both a financial…
Older Posts
Newer Posts

    SUBSCRIBE NOW


    Via Email
    Via Telephone


    I Agree. I would like to share my information with FinTechsDepot & their partners so that I can receive relevant information about products, services, & offers.

    RECENT POST

    • FinTech and Employee F&F Settlement: How Digital Financial Platforms Are Transforming the Employee Exit Process
    • How AI and Digital Innovation Are Transforming the Future of the FinTech Industry
    • The Power of Ecosystems for Banking
    • The Rise of Fintech: Transforming the Financial Landscape
    • Why Financial Services and Banks Need an Operational Data Layer

    ARTICLE

    Opción Yo Earns a Place Among the Top 3% of the Inc. 5000
    2026-08-13T12:51:07Z
    MIAMI, FL, Aug. 13, 2026 (GLOBE NEWSWIRE) -- — This recognition reflects a profound cultural shift as more people prioritize emotional well-being with the same intention they have long invested...


    Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth
    2026-08-13T12:51:00Z
    WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in...


    SS Innovations Reports Second Quarter 2026 Financial Results
    2026-08-13T12:30:00Z
    Record quarterly revenue driven by continuing strong growth in SSi Mantra unit sales


    Dogwood Therapeutics Announces Second Quarter 2026 Financial Results
    2026-08-13T12:30:00Z
    - Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026, 217 patients enrolled –


    PDS Biotech Reports Second Quarter 2026 Financial Results
    2026-08-13T12:30:00Z
    PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today...


    Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
    2026-08-13T12:30:00Z
    First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient with same-day discharge


    Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
    2026-08-13T12:30:00Z
    NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today...


    Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
    2026-08-13T12:30:00Z
    Cash and Cash Equivalents of $28.4 Million as of June 30, 2026 Providing Runway Through Mid-2027; Company Advances Chemistry, Manufacturing and Controls (CMC) Work Toward NDA Resubmission


    Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
    2026-08-13T12:05:00Z
    NEEDHAM, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for...


    WallabyPhenox Announces First Patient Enrolled in PROMISE Study Evaluating Treatment of Medium Vessel Occlusion Stroke
    2026-08-13T12:00:00Z
    IRVINE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- WallabyPhenox today announced that the first patient has been enrolled in PROMISE (PROspective study on Management of Ischemic Stroke secondary to mEvo),...


    Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
    2026-08-13T12:00:00Z
    Clinical and Scientific Progress Across the Pipeline Supports Multiple Upcoming Milestones


    Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
    2026-08-13T12:00:00Z
    VANCOUVER, British Columbia, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize...


    Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update
    2026-08-13T12:00:00Z
    PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of...


    Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit
    2026-08-13T12:00:00Z
    ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the...


    Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement 
    2026-08-13T12:00:00Z
    JUPITER, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ: DYAI) (the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences,...


    Cannara Establishes Automatic Share Purchase Plan
    2026-08-13T12:00:00Z
    MONTREAL, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, the “Company”, “us” or “we”) (TSX: LOVE) (OTCQX: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis products...


    Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint
    2026-08-13T11:36:00Z
    Clearmind Medicine has received Independent Data and Safety Monitoring Board (DSMB) approval to advance its clinical evaluation of CMND‑100 in patients with Alcohol Use Disorder (AUD) - a key milestone...


    Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives
    2026-08-13T11:30:00Z
    Agreement marks achievement of Cerenome’s full-year 2026 commercial payer coverage objective for CNSide


    MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
    2026-08-13T11:30:00Z
    NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapies for cancer and...


    Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
    2026-08-13T11:30:00Z
    Registrational RESET-Myositis® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel


    Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
    2026-08-13T11:30:00Z
    - Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million –


    Collegium Announces $50 Million Accelerated Share Repurchase Program
    2026-08-13T11:30:00Z
    STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood...


    NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates
    2026-08-13T11:30:00Z
    VANCOUVER, British Columbia, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and...


    Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
    2026-08-13T11:30:00Z
    ‒ Q2 2026 Consolidated Revenue of $101.9 million ‒


    Ascendis Pharma Reports Second Quarter 2026 Financial Results
    2026-08-13T11:30:00Z
    – Q2 2026 product revenue of €315 million (+105% Y/Y), comprising €252 million for YORVIPATH®, €55 million for SKYTROFA®, and €8 million for YUVIWEL®


    MediPharm Labs Reports Positive Q2 2026 Net Income and Second Consecutive Quarter of Positive Adjusted EBITDA
    2026-08-13T11:30:00Z
    TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today...


    Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
    2026-08-13T11:15:00Z
    FULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biopharmaceutical company developing novel therapies for cancer and other serious diseases, today...


    Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
    2026-08-13T11:15:00Z
    Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA’s Accelerated Approval Program


    Pelthos Therapeutics Announces Second Quarter 2026 Financial Results
    2026-08-13T11:10:00Z
    Zelsuvmi® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026


    ProQR Announces Second Quarter 2026 Operating and Financial Results
    2026-08-13T11:00:00Z
    LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) --  ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on...

    Copyright © 2026 | FinTechsDepot | All Rights Reserved |
    Privacy Policy | Unsubscribe
    Sign in

    Welcome, Login to your account.

    Forget password?
    Sign in

    Recover your password.

    A password will be e-mailed to you.